Abstract:Abstract Bone homeostasis and hematopoiesis are irrevocably linked in the hypoxic environment of the bone marrow. Erythropoietin (Epo) regulates erythropoiesis by binding to its receptor, Epor, on erythroid progenitor cells. The continuous process of bone remodeling is achieved by the finely balanced activity of osteoblasts in bone synthesis and osteoclasts in bone resorption. Both osteoblasts and osteoclasts express functional Epors, but the underlying mechanism of Epo-Epor signaling in bone homeostasis is incompletely understood. Two recent publications have provided new insights into the contribution of endogenous Epo to bone homeostasis. Suresh et al examined Epo-Epor signaling in osteoblasts in bone formation in mice and Deshet-Unger et al investigated osteoclastogenesis arising from transdifferentiation of B cells. Both groups also studied bone loss in mice caused by exogenous human recombinant EPO-stimulated erythropoiesis. They found that either deletion of Epor in osteoblasts or conditional knockdown of Epor in B cells attenuates EPO-driven bone loss. These findings have direct clinical implications because patients on long-term treatment for anemia may have an increased risk of bone fractures. Phase 3 trials of small molecule inhibitors of the PHD enzymes (hypoxia inducible factor-prolyl hydroxylase inhibitors [HIF-PHIs]), such as Roxadustat, have shown improved iron metabolism and increased circulating Epo levels in a titratable manner, avoiding the supraphysiologic increases that often accompany intravenous EPO therapy. The new evidence presented by Suresh and Deshet-Unger and their colleagues on the effects of EPO-stimulated erythropoiesis on bone homeostasis seems likely to stimulate discussion on the relative merits and safety of EPO and HIF-PHIs.

Research progress in erythropoietin mimetic peptides

Physiology and pharmacology of erythropoietin

Recent Progress in the Synthesis of Homogeneous Erythropoietin (EPO) Glycoforms

Synthesis and biological evaluation of (4-hydroxy-2-(substitued sulfonamido)pyrimidine-5-carbonyl)glycines as oral erythropoietin secretagogues

Biosimilar recombinant human erythropoietins ("epoetins") and future erythropoiesis-stimulating treatments

Preparation of A New Erythropoietin-derived Peptide

Updates on Novel Erythropoiesis-Stimulating Agents: Clinical and Molecular Approach

Theoretical Mutation Design of Active Agent of Eryhropoietin and Its Receptor

Pharmacokinetics and Pharmacodynamics of Recombinant Human EPO-Fc Fusion Protein in Vivo.

New avenues of exploration for erythropoietin

Challenges and recent advances in erythropoietin stability

Modeling and biological evaluation of pegmolesatide, a novel and potent erythropoiesis-stimulating agent

Design, selection, and development of cyclic peptide ligands for human erythropoietin

Recent Advances in the Detection of Recombinant Human Erythropoiesis and Its Analogs in Doping Control

From Erythropoietin to Its Peptide Derivatives: Smaller but Stronger.

Erythropoietin and Nonhematopoietic Effects

The protective effect of erythropoietin and its novel derived peptides in peripheral nerve injury

Progress of Erythropoietin for Patients with Renal Anemia

Clinical Application of Erythropoietin

Erythropoietin in bone homeostasis—Implications for efficacious anemia therapy

Research Progress of Erythropoietin in Ischemia/Reperfusion Injury